{"id":"pirfenidone-or-nintedanib","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Gastrointestinal disturbances (nausea, diarrhea, vomiting)"},{"rate":"10–20%","effect":"Photosensitivity (pirfenidone)"},{"rate":"5–15%","effect":"Elevated liver enzymes"},{"rate":"5–10%","effect":"Rash"},{"rate":"5–15%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1256391","moleculeType":"Small molecule","molecularWeight":"185.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pirfenidone acts as a general antifibrotic by inhibiting TGF-β signaling and reducing inflammatory cytokine production. Nintedanib is a tyrosine kinase inhibitor targeting FGFR, VEGFR, and PDGFR, which are key drivers of fibroblast activation and extracellular matrix deposition. Both drugs slow the decline in lung function in idiopathic pulmonary fibrosis (IPF).","oneSentence":"Pirfenidone and nintedanib are antifibrotic agents that reduce fibroblast proliferation and collagen deposition to slow lung fibrosis progression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:24.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Idiopathic pulmonary fibrosis (IPF)"}]},"trialDetails":[{"nctId":"NCT07491523","phase":"","title":"Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD","status":"RECRUITING","sponsor":"University of Patras","startDate":"2025-06-01","conditions":"SSc-Systemic Sclerosis","enrollment":35},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT07454291","phase":"PHASE1","title":"A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Endeavor Biomedicines, Inc.","startDate":"2026-03","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":57},{"nctId":"NCT05674994","phase":"PHASE3","title":"Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2023-10-26","conditions":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":110},{"nctId":"NCT03939520","phase":"PHASE4","title":"Management of Progressive Disease in Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2020-06-11","conditions":"Progressive Idiopathic Pulmonary Fibrosis","enrollment":279},{"nctId":"NCT05195918","phase":"PHASE1","title":"Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hal Chapman","startDate":"2023-08-24","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":50},{"nctId":"NCT05497284","phase":"PHASE2","title":"To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-10","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":46},{"nctId":"NCT07332117","phase":"","title":"A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications","status":"RECRUITING","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2025-09-09","conditions":"Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis","enrollment":30},{"nctId":"NCT07229716","phase":"PHASE1","title":"Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-11","conditions":"Pulmonary Fibrosis","enrollment":20},{"nctId":"NCT07015398","phase":"PHASE1","title":"A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants","status":"COMPLETED","sponsor":"Trevi Therapeutics","startDate":"2025-06-30","conditions":"Healthy Participants","enrollment":132},{"nctId":"NCT05483907","phase":"PHASE2","title":"To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF","status":"COMPLETED","sponsor":"Bridge Biotherapeutics, Inc.","startDate":"2023-04-12","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":129},{"nctId":"NCT03287414","phase":"PHASE2","title":"Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-20","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":30},{"nctId":"NCT04419506","phase":"PHASE2","title":"A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-07-28","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":147},{"nctId":"NCT03733444","phase":"PHASE3","title":"A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care","status":"TERMINATED","sponsor":"Galapagos NV","startDate":"2018-11-05","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":781},{"nctId":"NCT03711162","phase":"PHASE3","title":"A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care","status":"TERMINATED","sponsor":"Galapagos NV","startDate":"2018-11-28","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":525},{"nctId":"NCT05383131","phase":"PHASE1","title":"To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-06-23","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":33},{"nctId":"NCT05373914","phase":"PHASE2","title":"RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF)","status":"UNKNOWN","sponsor":"Blade Therapeutics","startDate":"2022-05-31","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":200},{"nctId":"NCT03958071","phase":"","title":"A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-02-01","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":13264},{"nctId":"NCT04888715","phase":"PHASE1","title":"To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-07-23","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":48},{"nctId":"NCT03725852","phase":"PHASE2","title":"A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2018-09-27","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":68},{"nctId":"NCT01890265","phase":"PHASE2","title":"Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2013-07-30","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":160},{"nctId":"NCT02606877","phase":"PHASE4","title":"A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-04-19","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3979,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"pirfenidone or nintedanib","genericName":"pirfenidone or nintedanib","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pirfenidone and nintedanib are antifibrotic agents that reduce fibroblast proliferation and collagen deposition to slow lung fibrosis progression. Used for Idiopathic pulmonary fibrosis (IPF).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}